Zi Chao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zi Chao Zhang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Junhai Han
School of Life Science and Technology, the Key Laboratory of Developmental Genes and Human Disease, Southeast University, 2 Dongda Road, Nanjing, China
14 shared publications Wenhua Liu
School of Life Science and Technology, the Key Laboratory of Developmental Genes and Human Disease, Southeast University, 2 Dongda Road, Nanjing, China
5 shared publicationsXian Liu
School of Life Science and Technology, The Key Laboratory of Developmental Genes and Human Disease, Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing 210096, China
5 shared publicationsShanshan Cheng
School of Life Science and Technology, the Key Laboratory of Developmental Genes and Human Disease, Southeast University, 2 Dongda Road, Nanjing, China
4 shared publications- Wei Xie
The Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, The School of Life Science and Technology, Southeast University, Nanjing, China
4 shared publications Yao Tian
School of Life Science and Technology, The Key Laboratory of Developmental Genes and Human Disease, Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing 210096, China
4 shared publications
Latest Publications
- 6 July 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (10) , 2693-2707
Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture
Purpose: Thyroid cancer is the most common malignancy of the endocrine system, with a rising global incidence. Radioactive iodine (RAI) therapy with 131I is used post-surgery to ablate residual thyroid tissue and cancer cells in differentiated thyroid cancer. However, in radioiodine-refractory cases, tumor cells often undergo dedifferentiation and develop RAI resistance, severely limiting therapeutic efficacy. Therefore, elucidating the mechanisms underlying dedifferentiation and developing strategies to restore differentiation have become a hot topic in thyroid cancer research. In this study, a three-dimensional (3D) culture model of TPC-1 thyroid cancer cells was developed using hanging drop and low-adhesion methods to mimic the dedifferentiation process in vitro. Cells cultured under 3D conditions exhibited typical dedifferentiated features, including upregulation of cancer stem cell markers, downregulation of thyroid functional proteins, and impaired radioiodine uptake. Through integrated bioinformatic analysis and immunohistochemical staining of in-house papillary thyroid carcinoma (PTC) samples, we identified transforming growth factor beta 1 (TGF-β1) as a potent inducer of thyroid cancer dedifferentiation. The TGF-β1/Smad signaling pathway was activated in PTC tissues, where it played a critical role in regulating tumor stemness and the expression of iodine-metabolizing proteins. Galunisertib, a TGF-β type I receptor kinase inhibitor, effectively blocked TGF-β1 signaling in spheroids, suppressed cancer stem cell marker expression, and enhanced radioiodine uptake through upregulation of thyroid functional proteins, establishing TGF-β1 as a therapeutic target in thyroid cancer. Collectively, the established 3D culture model serves as a robust platform for investigating dedifferentiation in thyroid cancer and provides a basis for developing novel therapies against radioiodine resistance. Plain Language
- 6 July 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (10) , 2693-2707
Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture
Purpose: Thyroid cancer is the most common malignancy of the endocrine system, with a rising global incidence. Radioactive iodine (RAI) therapy with 131I is used post-surgery to ablate residual thyroid tissue and cancer cells in differentiated thyroid cancer. However, in radioiodine-refractory cases, tumor cells often undergo dedifferentiation and develop RAI resistance, severely limiting therapeutic efficacy. Therefore, elucidating the mechanisms underlying dedifferentiation and developing strategies to restore differentiation have become a hot topic in thyroid cancer research. In this study, a three-dimensional (3D) culture model of TPC-1 thyroid cancer cells was developed using hanging drop and low-adhesion methods to mimic the dedifferentiation process in vitro. Cells cultured under 3D conditions exhibited typical dedifferentiated features, including upregulation of cancer stem cell markers, downregulation of thyroid functional proteins, and impaired radioiodine uptake. Through integrated bioinformatic analysis and immunohistochemical staining of in-house papillary thyroid carcinoma (PTC) samples, we identified transforming growth factor beta 1 (TGF-β1) as a potent inducer of thyroid cancer dedifferentiation. The TGF-β1/Smad signaling pathway was activated in PTC tissues, where it played a critical role in regulating tumor stemness and the expression of iodine-metabolizing proteins. Galunisertib, a TGF-β type I receptor kinase inhibitor, effectively blocked TGF-β1 signaling in spheroids, suppressed cancer stem cell marker expression, and enhanced radioiodine uptake through upregulation of thyroid functional proteins, establishing TGF-β1 as a therapeutic target in thyroid cancer. Collectively, the established 3D culture model serves as a robust platform for investigating dedifferentiation in thyroid cancer and provides a basis for developing novel therapies against radioiodine resistance. Plain Language
- Open Access
- 8 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The missense mutation Y65C in PQBP1 causes microcephaly and cognitive deficits through a combination of partial loss-of-function and gain-of-function effects
The missense mutation Y65C in polyglutamine-binding protein 1 (PQBP1) is associated with Renpenning syndrome, characterized by X-linked intellectual disability and microcephaly. However, the pathogenic mechanism underlying the microcephaly induced by the Y65C mutation remains unclear. In this study, we generated Pqbp1Y65C/Y knock-in male mice and discovered that the Y65C mutation impairs the proliferation of apical progenitors and their subsequent transition to basal progenitors, resulting in microcephaly and cognitive deficits like those observed in Renpenning syndrome patients. This Y65C substitution induces PQBP1 misfolding, which reduces PQBP1 protein levels and consequently impedes apical progenitor proliferation. Unexpectedly, the Y65C mutation also induces a gain-of-function that interferes with the transition from apical to basal progenitors by enhancing interactions with the core components of the mRNA 3’ end processing machinery, thereby preserving proliferative alternative polyadenylation (APA) profiles. Our study demonstrates that a combination of loss-of-function and gain-of-function contributes to the microcephaly caused by the Y65C mutation.
- 8 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe missense mutation Y65C in PQBP1 causes microcephaly and cognitive deficits through a combination of partial loss-of-function and gain-of-function effects
The missense mutation Y65C in polyglutamine-binding protein 1 (PQBP1) is associated with Renpenning syndrome, characterized by X-linked intellectual disability and microcephaly. However, the pathogenic mechanism underlying the microcephaly induced by the Y65C mutation remains unclear. In this study, we generated Pqbp1Y65C/Y knock-in male mice and discovered that the Y65C mutation impairs the proliferation of apical progenitors and their subsequent transition to basal progenitors, resulting in microcephaly and cognitive deficits like those observed in Renpenning syndrome patients. This Y65C substitution induces PQBP1 misfolding, which reduces PQBP1 protein levels and consequently impedes apical progenitor proliferation. Unexpectedly, the Y65C mutation also induces a gain-of-function that interferes with the transition from apical to basal progenitors by enhancing interactions with the core components of the mRNA 3’ end processing machinery, thereby preserving proliferative alternative polyadenylation (APA) profiles. Our study demonstrates that a combination of loss-of-function and gain-of-function contributes to the microcephaly caused by the Y65C mutation.
- Open Access
- 21 July 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (8) , 114525
Dynamic regulation of alternative polyadenylation by PQBP1 during neurogenesis
- 21 July 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (8) , 114525
Open AccessDynamic regulation of alternative polyadenylation by PQBP1 during neurogenesis
- 20 October 2023
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 200,p. e65787
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Sleep, an essential component of health and overall well-being, often presents challenges for older individuals who frequently experience sleep disorders characterized by shortened sleep duration and fragmented patterns. These sleep disruptions also correlate with an increased risk of various illnesses in the elderly, including diabetes, cardiovascular diseases, and psychological disorders. Unfortunately, existing drugs for sleep disorders are associated with significant side effects such as cognitive impairment and addiction. Consequently, the development of new, safer, and more effective sleep disorder medications is urgently needed. However, the high cost and lengthy experimental duration of current drug screening methods remain limiting factors. This protocol describes a cost-effective and high-throughput screening method that utilizes Drosophila melanogaster, a species with a highly conserved sleep regulation mechanism compared to mammals, making it an ideal model for studying sleep disorders in the elderly. By administering various small compounds to aged flies, we can assess their effects on sleep disorders. The sleep behaviors of these flies are recorded using an infrared monitoring device and analyzed with the open-source data package Sleep and Circadian Analysis MATLAB Program 2020 (SCAMP2020). This protocol offers a low-cost, reproducible, and efficient screening approach for sleep regulation. Fruit flies, due to their short life cycle, low husbandry cost, and ease of handling, serve as excellent subjects for this method. As an illustration, Reserpine, one of the tested drugs, demonstrated the ability to promote sleep duration in elderly flies, highlighting the effectiveness of this protocol.
- 20 October 2023
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 200,p. e65787
High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Sleep, an essential component of health and overall well-being, often presents challenges for older individuals who frequently experience sleep disorders characterized by shortened sleep duration and fragmented patterns. These sleep disruptions also correlate with an increased risk of various illnesses in the elderly, including diabetes, cardiovascular diseases, and psychological disorders. Unfortunately, existing drugs for sleep disorders are associated with significant side effects such as cognitive impairment and addiction. Consequently, the development of new, safer, and more effective sleep disorder medications is urgently needed. However, the high cost and lengthy experimental duration of current drug screening methods remain limiting factors. This protocol describes a cost-effective and high-throughput screening method that utilizes Drosophila melanogaster, a species with a highly conserved sleep regulation mechanism compared to mammals, making it an ideal model for studying sleep disorders in the elderly. By administering various small compounds to aged flies, we can assess their effects on sleep disorders. The sleep behaviors of these flies are recorded using an infrared monitoring device and analyzed with the open-source data package Sleep and Circadian Analysis MATLAB Program 2020 (SCAMP2020). This protocol offers a low-cost, reproducible, and efficient screening approach for sleep regulation. Fruit flies, due to their short life cycle, low husbandry cost, and ease of handling, serve as excellent subjects for this method. As an illustration, Reserpine, one of the tested drugs, demonstrated the ability to promote sleep duration in elderly flies, highlighting the effectiveness of this protocol.
- Open Access
- 21 March 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (3) , 112277
PQBP1 regulates striatum development through balancing striatal progenitor proliferation and differentiation
- 21 March 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (3) , 112277
Open AccessPQBP1 regulates striatum development through balancing striatal progenitor proliferation and differentiation
- 23 February 2023
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 51 (1) , 363-372
The role of PQBP1 in neural development and function
Mutations in the polyglutamine tract-binding protein 1 (PQBP1) gene are associated with Renpenning syndrome, which is characterized by microcephaly, intellectual deficiency, short stature, small testes, and distinct facial dysmorphism. Studies using different models have revealed that PQBP1 plays essential roles in neural development and function. In this mini-review, we summarize recent findings relating to the roles of PQBP1 in these processes, including in the regulation of neural progenitor proliferation, neural projection, synaptic growth, neuronal survival, and cognitive function via mRNA transcription and splicing-dependent or -independent processes. The novel findings provide insights into the mechanisms underlying the pathogenesis of Renpenning syndrome and may advance drug discovery and treatment for this condition.
- 23 February 2023
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 51 (1) , 363-372
The role of PQBP1 in neural development and function
Mutations in the polyglutamine tract-binding protein 1 (PQBP1) gene are associated with Renpenning syndrome, which is characterized by microcephaly, intellectual deficiency, short stature, small testes, and distinct facial dysmorphism. Studies using different models have revealed that PQBP1 plays essential roles in neural development and function. In this mini-review, we summarize recent findings relating to the roles of PQBP1 in these processes, including in the regulation of neural progenitor proliferation, neural projection, synaptic growth, neuronal survival, and cognitive function via mRNA transcription and splicing-dependent or -independent processes. The novel findings provide insights into the mechanisms underlying the pathogenesis of Renpenning syndrome and may advance drug discovery and treatment for this condition.
- Open Access
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100679
Protocol for interfering peptide injection into adult mouse hippocampus and spatial memory testing
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100679
Open AccessProtocol for interfering peptide injection into adult mouse hippocampus and spatial memory testing
- Open Access
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100616
Protocol for visualizing newly synthesized proteins in primary mouse hepatocytes
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100616
Open AccessProtocol for visualizing newly synthesized proteins in primary mouse hepatocytes
- 1 April 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (7) , 1425-1438.e10
PQBP1 promotes translational elongation and regulates hippocampal mGluR-LTD by suppressing eEF2 phosphorylation
- 1 April 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (7) , 1425-1438.e10
PQBP1 promotes translational elongation and regulates hippocampal mGluR-LTD by suppressing eEF2 phosphorylation
- Open Access
- 18 March 2021
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 13 (5) , 392-394
Novel regulation of the eEF2K/eEF2 pathway: prospects of ‘PQBP1 promotes translational elongation and regulates hippocampal mGluR-LTD by suppressing eEF2 phosphorylation’
Protein synthesis involves initiation, elongation, and termination. A number of studies show that translation elongation is highly regulated and is the most energy-intensive process, which controls the efficiency and accuracy of protein synthesis. In the elongation process, eukaryotic elongation factor 2 (eEF2) binds to the ribosome to induce its conformation change and promotes the translocation of the tRNAs by hydrolyzing guanosine triphosphate, which then allows the next AA-tRNA to enter the A site for translation elongation. The activity of eEF2 is negatively regulated by its kinase eEF2K that phosphorylates eEF2 at threonine-56 (Thr56). Dysregulation of elongation is the core of the pathogenesis of tumorigenesis and neurodegeneration. Thus, eEF2/eEF2K as a potential therapeutic target has attracted more and more attention ( Knight et al., 2020). In a recently published work, we identified that the intellectual disability related protein, polyglutamine-binding protein 1 (PQBP1), is a novel regulator that binds directly with eEF2 and affects its phosphorylation ( Figure 1; Shen et al., 2021).
- 18 March 2021
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 13 (5) , 392-394
Open AccessNovel regulation of the eEF2K/eEF2 pathway: prospects of ‘PQBP1 promotes translational elongation and regulates hippocampal mGluR-LTD by suppressing eEF2 phosphorylation’
Protein synthesis involves initiation, elongation, and termination. A number of studies show that translation elongation is highly regulated and is the most energy-intensive process, which controls the efficiency and accuracy of protein synthesis. In the elongation process, eukaryotic elongation factor 2 (eEF2) binds to the ribosome to induce its conformation change and promotes the translocation of the tRNAs by hydrolyzing guanosine triphosphate, which then allows the next AA-tRNA to enter the A site for translation elongation. The activity of eEF2 is negatively regulated by its kinase eEF2K that phosphorylates eEF2 at threonine-56 (Thr56). Dysregulation of elongation is the core of the pathogenesis of tumorigenesis and neurodegeneration. Thus, eEF2/eEF2K as a potential therapeutic target has attracted more and more attention ( Knight et al., 2020). In a recently published work, we identified that the intellectual disability related protein, polyglutamine-binding protein 1 (PQBP1), is a novel regulator that binds directly with eEF2 and affects its phosphorylation ( Figure 1; Shen et al., 2021).